{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:09:05Z","timestamp":1789114145404,"version":"build-2803163510"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Immune checkpoint inhibitors have transformed cancer treatment, but immune-related adverse events (irAEs) may affect almost any organ and can progress rapidly when early manifestations are overlooked. Because nurses perform repeated assessment, laboratory review, symptom triage, patient education, and coordination across treatment cycles, nurse-coordinated monitoring is a clinically relevant component of ICI safety. This targeted narrative Mini Review distinguishes four biomarker functions: pretreatment prediction of future irAE risk, longitudinal surveillance, diagnostic support after symptoms or laboratory abnormalities emerge, and severity or outcome prognostication. Complete blood count-derived indices, C-reactive protein, albumin, lactate dehydrogenase, ferritin, cytokines, autoantibodies, and immune-cell subsets provide non-interchangeable signals, while organ-directed tests may identify thyroid, adrenal, hepatic, renal, pancreatic, cardiac, neuromuscular, or pulmonary injury. We discuss the immunobiological links between checkpoint blockade, loss of peripheral tolerance, autoreactive lymphocytes, cytokine amplification, and measurable laboratory changes. We further propose an implementation framework based on baseline assessment, standardized serial testing, trend interpretation, symptom correlation, electronic patient-reported outcomes, and predefined escalation pathways. Here, \u201cearly warning\u201d means recognition of a reproducible symptom or biomarker trajectory that prompts evaluation before Common Terminology Criteria for Adverse Events grade progression or hospitalization; it does not imply universally presymptomatic detection. No single biomarker currently provides sufficient sensitivity or specificity for routine prediction or diagnosis. Biomarker trends should therefore complement, not replace, clinical assessment and responsible medical decision-making.<\/jats:p>","DOI":"10.3389\/fmed.2026.1949715","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:16:57Z","timestamp":1789111017000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Nurse-coordinated biomarker and symptom monitoring for immune checkpoint inhibitor toxicity"],"prefix":"10.3389","volume":"13","author":[{"given":"Yun","family":"Feng","sequence":"first","affiliation":[{"name":"School of Nursing, Zhejiang Chinese Medical University","place":["Hangzhou, Zhejiang, China"]},{"name":"Department of Anesthesiology and Operating Room, Zhejiang Hospital","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Zhejiang Hospital","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenlian","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Operating Room, Zhejiang Hospital","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: aSCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: eSMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br J Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00228-024-03647-z","article-title":"Immune-related serious adverse events with immune checkpoint inhibitors: systematic review and network meta-analysis","volume":"80","author":"Oliveira","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.alit.2022.01.001","article-title":"Immune-related adverse events in various organs caused by immune checkpoint inhibitors","volume":"71","author":"Okiyama","year":"2022","journal-title":"Allergol Int"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e006500","DOI":"10.1136\/jitc-2022-006500","article-title":"Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review","volume":"11","author":"Barron","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/25785826.2021.1976942","article-title":"Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy","volume":"45","author":"Kubo","year":"2022","journal-title":"Immunol Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.rdc.2024.01.004","article-title":"The current and future of biomarkers of immune related adverse events","volume":"50","author":"Bracamonte-Baran","year":"2024","journal-title":"Rheum Dis Clin North Am"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3390\/cancers16061225","article-title":"Non-invasive predictive biomarkers for immune-related adverse events due to immune checkpoint inhibitors","volume":"16","author":"Ponvilawan","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1177\/00045632241312629","article-title":"The use of peripheral blood biomarkers for predicting the risk of immune-related adverse events in immune checkpoint inhibitor therapy","volume":"62","author":"Duvall","year":"2025","journal-title":"Ann Clin Biochem"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12865-024-00599-y","article-title":"Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors","volume":"25","author":"Wang","year":"2024","journal-title":"BMC Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1082084","DOI":"10.3389\/fimmu.2022.1082084","article-title":"Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells","volume":"13","author":"Gazzano","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ccell.2022.02.015","article-title":"A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events","volume":"40","author":"Goswami","year":"2022","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"991433","DOI":"10.3389\/fimmu.2022.991433","article-title":"Checkpoint inhibitor immune-related adverse events: a focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities","volume":"13","author":"Taylor","year":"2022","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e004008","DOI":"10.1136\/jitc-2021-004008","article-title":"Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition","volume":"10","author":"Ghosh","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2204754","DOI":"10.1080\/2162402X.2023.2204754","article-title":"Preexisting autoantibodies as predictor of immune related adverse events for advanced solid tumors treated with immune checkpoint inhibitors","volume":"12","author":"Daban","year":"2023","journal-title":"Oncoimmunology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s10238-024-01317-z","article-title":"Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort","volume":"24","author":"Ceccarelli","year":"2024","journal-title":"Clin Exp Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e2200348119","DOI":"10.1073\/pnas.2200348119","article-title":"Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota","volume":"119","author":"Hu","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B20","doi-asserted-by":"publisher","first-page":"eabn9644","DOI":"10.1126\/sciimmunol.abn9644","article-title":"Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade","volume":"7","author":"Berner","year":"2022","journal-title":"Sci Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"111611","DOI":"10.1016\/j.celrep.2022.111611","article-title":"Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis","volume":"41","author":"Won","year":"2022","journal-title":"Cell Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1053\/j.gastro.2021.06.025","article-title":"Interferon-gamma-producing CD8-positive tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis","volume":"161","author":"Sasson","year":"2021","journal-title":"Gastroenterology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1381250","DOI":"10.3389\/fonc.2024.1381250","article-title":"The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis","volume":"14","author":"Zhao","year":"2024","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1213225","DOI":"10.3389\/fendo.2023.1213225","article-title":"Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus","volume":"14","author":"Shen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.jhepr.2023.100851","article-title":"Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: a 10-year real-world retrospective cohort study","volume":"5","author":"Atallah","year":"2023","journal-title":"JHEP Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e009742","DOI":"10.1136\/jitc-2024-009742","article-title":"Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events","volume":"12","author":"Shatila","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00262-024-03834-y","article-title":"Bronchoalveolar lavage fluid analysis in patients with checkpoint inhibitor pneumonitis","volume":"73","author":"Chen","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e010114","DOI":"10.1136\/jitc-2024-010114","article-title":"Krebs von den lungen-6 surveillance in immune checkpoint inhibitor-induced pneumonitis","volume":"12","author":"Matsukane","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e002553","DOI":"10.1136\/jitc-2021-002553","article-title":"Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis","volume":"9","author":"Puzanov","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"115186","DOI":"10.1016\/j.ejca.2024.115186","article-title":"Optimized monitoring for immune checkpoint inhibitor induced myocarditis using high-sensitivity troponin-T","volume":"216","author":"Tomsitz","year":"2025","journal-title":"Eur J Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1002\/ehf2.14340","article-title":"Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor-associated cardiotoxicity","volume":"10","author":"Liang","year":"2023","journal-title":"ESC Heart Fail"},{"key":"B33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/cancers16020340","article-title":"Incidence of cutaneous immune-related adverse events and outcomes in immune checkpoint inhibitor-containing regimens: a systematic review and meta-analysis","volume":"16","author":"Curkovic","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"100076","DOI":"10.1016\/j.apjon.2022.100076","article-title":"Exploring the educational needs for severe immune-related adverse events of PD-1\/PD-L1 inhibitors in advanced lung cancer: a single-center observational study","volume":"9","author":"Aso","year":"2022","journal-title":"Asia Pac J Oncol Nurs"},{"key":"B35","doi-asserted-by":"publisher","first-page":"102194","DOI":"10.1016\/j.ejon.2022.102194","article-title":"A pilot randomized controlled study of the effects of an educational training program on skin reactions induced by chemotherapy, epidermal growth factor inhibitor treatments, and immunotherapy","volume":"60","author":"Papoui","year":"2022","journal-title":"Eur J Oncol Nurs"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e2200185","DOI":"10.1200\/CCI.22.00185","article-title":"The feasibility, acceptability, and effectiveness of electronic patient-reported outcome symptom monitoring for immune checkpoint inhibitor toxicities: a systematic review","volume":"7","author":"Lai-Kwon","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e2122998","DOI":"10.1001\/jamanetworkopen.2021.22998","article-title":"Evaluation of technology-enabled monitoring of patient-reported outcomes to detect and treat toxic effects linked to immune checkpoint inhibitors","volume":"4","author":"Msaouel","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e48386","DOI":"10.2196\/48386","article-title":"Testing a model of care for patients on immune checkpoint inhibitors based on electronic patient-reported outcomes: protocol for a randomized phase II controlled trial","volume":"12","author":"da Silva Lopes","year":"2023","journal-title":"JMIR Res Protoc"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5841","DOI":"10.1007\/s00432-022-04504-1","article-title":"Implementing an immunotherapy toxicity GI service improves outcomes in patients with immune-mediated diarrhea and colitis","volume":"149","author":"Saji","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"100787","DOI":"10.1016\/j.esmoop.2023.100787","article-title":"Immune-related adverse events as potential surrogates of immune checkpoint inhibitors\u2019 efficacy: a systematic review and meta-analysis of randomized studies","volume":"8","author":"Amoroso","year":"2023","journal-title":"ESMO Open"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1281645","DOI":"10.3389\/fonc.2024.1281645","article-title":"Immune-related adverse events and their effects on survival outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Liang","year":"2024","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/hed.27388","article-title":"Patient-reported outcomes in immunotherapy for head and neck cancer","volume":"45","author":"Kirtane","year":"2023","journal-title":"Head Neck"},{"key":"B43","doi-asserted-by":"publisher","first-page":"103919","DOI":"10.1016\/j.critrevonc.2023.103919","article-title":"Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: a systematic scoping review","volume":"183","author":"Egeler","year":"2023","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1949715\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:16:58Z","timestamp":1789111018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1949715\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":43,"alternative-id":["10.3389\/fmed.2026.1949715"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1949715","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"article-number":"1949715"}}